- Home
- GOSS vs IKT Comparison
GOSS vs IKT Comparison
Compare GOSS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- IKT
- Stock Information
- Founded
- GOSS 2015
- IKT 2008
- Country
- GOSS United States
- IKT United States
- Employees
- GOSS N/A
- IKT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- IKT Health Care
- Exchange
- GOSS Nasdaq
- IKT Nasdaq
- Market Cap
- GOSS 188.6M
- IKT 167.2M
- IPO Year
- GOSS 2019
- IKT 2020
- Fundamental
- Price
- GOSS $0.84
- IKT $1.90
- Analyst Decision
- GOSS Strong Buy
- IKT Buy
- Analyst Count
- GOSS 4
- IKT 2
- Target Price
- GOSS $7.50
- IKT $8.00
- AVG Volume (30 Days)
- GOSS 1.5M
- IKT 147.0K
- Earning Date
- GOSS 05-06-2025
- IKT 05-14-2025
- Dividend Yield
- GOSS N/A
- IKT N/A
- EPS Growth
- GOSS N/A
- IKT N/A
- EPS
- GOSS N/A
- IKT N/A
- Revenue
- GOSS $114,701,000.00
- IKT N/A
- Revenue This Year
- GOSS N/A
- IKT N/A
- Revenue Next Year
- GOSS $172.31
- IKT N/A
- P/E Ratio
- GOSS N/A
- IKT N/A
- Revenue Growth
- GOSS N/A
- IKT N/A
- 52 Week Low
- GOSS $0.50
- IKT $1.12
- 52 Week High
- GOSS $1.55
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- GOSS 37.58
- IKT 42.84
- Support Level
- GOSS $0.80
- IKT $1.58
- Resistance Level
- GOSS $0.88
- IKT $2.22
- Average True Range (ATR)
- GOSS 0.10
- IKT 0.22
- MACD
- GOSS -0.01
- IKT 0.00
- Stochastic Oscillator
- GOSS 20.24
- IKT 45.57
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.